Virbac USA

News

Latest Announcements

VIRBAC CORPORATION NAMES COURTNEY CARNEY DIRECTOR OF MARKETING, PARASITICIDES

06/12/2015

Fort Worth, Texas (June 12, 2015) – Virbac Corporation today announced that Mrs. Courtney Carney has been named Director of Marketing, Parasiticides. In this new role, Mrs. Carney will be responsible for planning, directing and providing market leadership for Virbac’s extensive parasiticide franchise in the U.S.

Read more

VIRBAC CORPORATION NAMES ROBERT “MAC” MACGREGOR VICE PRESIDENT, INDUSTRIAL OPERATIONS

05/18/2015

Fort Worth, Texas (May 18, 2015) – Virbac Corporation today announced that Mr. Robert “Mac” MacGregor has been named Vice President, Industrial Operations, effective immediately. In this role, Mr. MacGregor will be responsible for North American Industrial Operations, encompassing planning, directing and coordinating all manufacturing activities, to efficiently supply customers based upon their needs and pharmaceutical/regulatory requirements.

Read more

VIRBAC CORPORATION STRENGTHENS SALES ORGANIZATION

04/02/2015

Fort Worth, Texas (April 2, 2015) – Virbac Corporation today announced the promotions of three individuals, Naomi Potts, Bryan Armstrong and Mary Jo McNeily to Sales Director Roles. In these new roles, they will report directly to Jim Van Proosdy, Vice President of Sales for Virbac U.S.

Read more

VIRBAC ANNOUNCES THE CLOSING OF THE SENTINEL® BRANDS FAMILY ACQUISITION IN THE U.S.

01/15/2015

Fort Worth, Texas (January 5, 2015) – Virbac announces the successful closing, on January 2nd, of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM®, previously marketed by Novartis Animal Health.

Read more

VIRBAC ANNOUNCES THAT IT HAS ENTERED INTO AGREEMENT WITH ELI LILLY AND COMPANY

10/27/2014

Fort Worth, Texas (October 27, 2014) – Virbac Corporation today announced that it has entered into an agreement with Eli Lilly and Company to acquire major U.S. veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Read more

Subscribe